These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 37117112)

  • 21. Effects of Initial Gleason Grade on Outcomes during Active Surveillance for Prostate Cancer.
    Masic S; Cowan JE; Washington SL; Nguyen HG; Shinohara K; Cooperberg MR; Carroll PR
    Eur Urol Oncol; 2018 Oct; 1(5):386-394. PubMed ID: 31158077
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A novel nomogram to identify candidates for active surveillance amongst patients with International Society of Urological Pathology (ISUP) Grade Group (GG) 1 or ISUP GG2 prostate cancer, according to multiparametric magnetic resonance imaging findings.
    Luzzago S; de Cobelli O; Cozzi G; Peveri G; Bagnardi V; Catellani M; Di Trapani E; Mistretta FA; Pricolo P; Conti A; Alessi S; Marvaso G; Ferro M; Matei DV; Renne G; Jereczek-Fossa BA; Petralia G; Musi G
    BJU Int; 2020 Jul; 126(1):104-113. PubMed ID: 32150328
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Practice patterns related to prostate cancer grading: results of a 2019 Genitourinary Pathology Society clinician survey.
    Fine SW; Trpkov K; Amin MB; Algaba F; Aron M; Baydar DE; Beltran AL; Brimo F; Cheville JC; Colecchia M; Comperat E; Costello T; da Cunha IW; Delprado W; DeMarzo AM; Giannico GA; Gordetsky JB; Guo CC; Hansel DE; Hirsch MS; Huang J; Humphrey PA; Jimenez RE; Khani F; Kong MX; Kryvenko ON; Kunju LP; Lal P; Latour M; Lotan T; Maclean F; Magi-Galluzzi C; Mehra R; Menon S; Miyamoto H; Montironi R; Netto GJ; Nguyen JK; Osunkoya AO; Parwani A; Pavlovich CP; Robinson BD; Rubin MA; Shah RB; So JS; Takahashi H; Tavora F; Tretiakova MS; True L; Wobker SE; Yang XJ; Zhou M; Zynger DL; Epstein JI
    Urol Oncol; 2021 May; 39(5):295.e1-295.e8. PubMed ID: 32948433
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Long-term Results of Active Surveillance in the Göteborg Randomized, Population-based Prostate Cancer Screening Trial.
    Godtman RA; Holmberg E; Khatami A; Pihl CG; Stranne J; Hugosson J
    Eur Urol; 2016 Nov; 70(5):760-766. PubMed ID: 27090975
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Primary Gleason grade 4 at the positive margin is associated with metastasis and death among patients with Gleason 7 prostate cancer undergoing radical prostatectomy.
    Viers BR; Sukov WR; Gettman MT; Rangel LJ; Bergstralh EJ; Frank I; Tollefson MK; Thompson RH; Boorjian SA; Karnes RJ
    Eur Urol; 2014 Dec; 66(6):1116-24. PubMed ID: 25052213
    [TBL] [Abstract][Full Text] [Related]  

  • 26. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prostate-only Versus Whole-pelvis Radiation with or Without a Brachytherapy Boost for Gleason Grade Group 5 Prostate Cancer: A Retrospective Analysis.
    Sandler KA; Cook RR; Ciezki JP; Ross AE; Pomerantz MM; Nguyen PL; Shaikh T; Tran PT; Stock RG; Merrick GS; Demanes DJ; Spratt DE; Abu-Isa EI; Wedde TB; Lilleby W; Krauss DJ; Shaw GK; Alam R; Reddy CA; Song DY; Klein EA; Stephenson AJ; Tosoian JJ; Hegde JV; Yoo SM; Fiano R; D'Amico AV; Nickols NG; Aronson WJ; Sadeghi A; Greco SC; Deville C; McNutt T; DeWeese TL; Reiter RE; Said JW; Steinberg ML; Horwitz EM; Kupelian PA; King CR; Kishan AU
    Eur Urol; 2020 Jan; 77(1):3-10. PubMed ID: 30992160
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A Prospective Adaptive Utility Trial to Validate Performance of a Novel Urine Exosome Gene Expression Assay to Predict High-grade Prostate Cancer in Patients with Prostate-specific Antigen 2-10ng/ml at Initial Biopsy.
    McKiernan J; Donovan MJ; Margolis E; Partin A; Carter B; Brown G; Torkler P; Noerholm M; Skog J; Shore N; Andriole G; Thompson I; Carroll P
    Eur Urol; 2018 Dec; 74(6):731-738. PubMed ID: 30237023
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A 17-gene assay to predict prostate cancer aggressiveness in the context of Gleason grade heterogeneity, tumor multifocality, and biopsy undersampling.
    Klein EA; Cooperberg MR; Magi-Galluzzi C; Simko JP; Falzarano SM; Maddala T; Chan JM; Li J; Cowan JE; Tsiatis AC; Cherbavaz DB; Pelham RJ; Tenggara-Hunter I; Baehner FL; Knezevic D; Febbo PG; Shak S; Kattan MW; Lee M; Carroll PR
    Eur Urol; 2014 Sep; 66(3):550-60. PubMed ID: 24836057
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Impact of a protein-based assay that predicts prostate cancer aggressiveness on urologists' recommendations for active treatment or active surveillance: a randomized clinical utility trial.
    Peabody JW; DeMaria LM; Tamondong-Lachica D; Florentino J; Czarina Acelajado M; Ouenes O; Richie JP; Burgon T
    BMC Urol; 2017 Jul; 17(1):51. PubMed ID: 28673277
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Active Surveillance for Low and Intermediate Risk Prostate Cancer: Opinions of North American Genitourinary Oncology Expert Radiation Oncologists.
    McClelland S; Sandler KA; Degnin C; Chen Y; Mitin T
    Clin Genitourin Cancer; 2018 Apr; 16(2):e323-e325. PubMed ID: 29174501
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A Decade of Active Surveillance in the PRIAS Study: An Update and Evaluation of the Criteria Used to Recommend a Switch to Active Treatment.
    Bokhorst LP; Valdagni R; Rannikko A; Kakehi Y; Pickles T; Bangma CH; Roobol MJ;
    Eur Urol; 2016 Dec; 70(6):954-960. PubMed ID: 27329565
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Should grade group 1 prostate cancer be reclassified as "non-cancer"? A pathology community perspective.
    Zhou M; Amin A; Fine SW; Rao P; Siadat F; Shah RB
    Urol Oncol; 2023 Feb; 41(2):62-64. PubMed ID: 36428166
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A national survey of radiation oncologists and urologists on recommendations of prostate-specific antigen screening for prostate cancer.
    Kim SP; Karnes RJ; Nguyen PL; Ziegenfuss JY; Thompson RH; Han LC; Shah ND; Smaldone MC; Gross CP; Frank I; Weight CJ; Beebe TJ; Tilburt JC
    BJU Int; 2014 May; 113(5b):E106-11. PubMed ID: 24053213
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Latest Evidence on the Impact of Smoking, Sports, and Sexual Activity as Modifiable Lifestyle Risk Factors for Prostate Cancer Incidence, Recurrence, and Progression: A Systematic Review of the Literature by the European Association of Urology Section of Oncological Urology (ESOU).
    Brookman-May SD; Campi R; Henríquez JDS; Klatte T; Langenhuijsen JF; Brausi M; Linares-Espinós E; Volpe A; Marszalek M; Akdogan B; Roll C; Stief CG; Rodriguez-Faba O; Minervini A
    Eur Urol Focus; 2019 Sep; 5(5):756-787. PubMed ID: 29576530
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A Multivariable Approach Using Magnetic Resonance Imaging to Avoid a Protocol-based Prostate Biopsy in Men on Active Surveillance for Prostate Cancer-Data from the International Multicenter Prospective PRIAS Study.
    Luiting HB; Remmers S; Boevé ER; Valdagni R; Chiu PK; Semjonow A; Berge V; Tully KH; Rannikko AS; Staerman F; Roobol MJ
    Eur Urol Oncol; 2022 Dec; 5(6):651-658. PubMed ID: 35437217
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Assessment of the Rate of Adherence to International Guidelines for Androgen Deprivation Therapy with External-beam Radiation Therapy: A Population-based Study.
    Dell'Oglio P; Abou-Haidar H; Leyh-Bannurah SR; Tian Z; Larcher A; Gandaglia G; Fossati N; Shariat SF; Capitanio U; Briganti A; Montorsi F; Graefen M; Saad F; Karakiewicz PI
    Eur Urol; 2016 Sep; 70(3):429-35. PubMed ID: 26951945
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A national survey of radiation oncologists and urologists on prediction tools and nomograms for localized prostate cancer.
    Gershman B; Maroni P; Tilburt JC; Volk RJ; Konety B; Bennett CL; Kutikov A; Smaldone MC; Chen V; Kim SP
    World J Urol; 2019 Oct; 37(10):2099-2108. PubMed ID: 30671637
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A Contemporary Prostate Cancer Grading System: A Validated Alternative to the Gleason Score.
    Epstein JI; Zelefsky MJ; Sjoberg DD; Nelson JB; Egevad L; Magi-Galluzzi C; Vickers AJ; Parwani AV; Reuter VE; Fine SW; Eastham JA; Wiklund P; Han M; Reddy CA; Ciezki JP; Nyberg T; Klein EA
    Eur Urol; 2016 Mar; 69(3):428-35. PubMed ID: 26166626
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Reporting Practices and Resource Utilization in the Era of Intraductal Carcinoma of the Prostate: A Survey of Genitourinary Subspecialists.
    Gandhi JS; Smith SC; Paner GP; McKenney JK; Sekhri R; Osunkoya AO; Baras AS; DeMarzo AM; Cheville JC; Jimenez RE; Trpkov K; Colecchia M; Ro JY; Montironi R; Menon S; Hes O; Williamson SR; Hirsch MS; Netto GJ; Fine SW; Sirohi D; Kaushal S; Sangoi A; Robinson BD; Kweldam CF; Humphrey PA; Hansel DE; Schultz L; Magi-Galluzzi C; Przybycin CG; Shah RB; Mehra R; Kunju LP; Aron M; Kryvenko ON; Kench JG; Kuroda N; Tavora F; van der Kwast T; Grignon DJ; Epstein JI; Reuter VE; Amin MB
    Am J Surg Pathol; 2020 May; 44(5):673-680. PubMed ID: 31876580
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.